Sign inJoin waitlistJoin the waitlist

Thomas Martin

Internal Medicine · Ucsf Medical Group Business Services

Credentials: · ·

History

Hematology and Medical Oncology
University of California (San Francisco) School of Medicine
1995–1998
University of California (San Francisco) School of Medicine
1992–1995
Internal Medicine
Ronald Reagan UCLA Medical Center
1989–1992
University of Connecticut School of Medicine
1985–1989

Research

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a…
The Lancet · 2021 · 1,514 citations
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2022 · 1,060 citations
Lenalidomide after stem-cell transplantation for multiple myeloma
New England Journal of Medicine · 2012 · 909 citations

Jeffrey Wolf
55 papers
SW
Sandy Wong
33 papers
NS
Nina Shah
26 papers
Lloyd Damon
21 papers
Saad Usmani
21 papers
Shaji Kumar
21 papers
Ajai Chari
20 papers
Joseph Mikhael
18 papers
Sundar Jagannath
18 papers
MH
Maung Htut
17 papers
Ravi Vij
17 papers
Shagun Arora
17 papers

Clinical trials

Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Principal investigator · Withdrawn · Phase 2
Thomas Martin, MD
2021–2022
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Principal investigator · Completed · Phase 1
Thomas Martin, MD
2015–2025
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Principal investigator · Completed
University of California, San Francisco
2010–2011
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Principal investigator · Completed
University of California, San Francisco
2005–2007